Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Source: 
Fierce Pharma
News Tags: 
snippet: 

The U.S. cost-effectiveness watchdog ICER plans to put its number crunching to work on price hikes. With the help of some new funding, the group plans to unveil in October its first annual list of increases that aren't supported by new clinical evidence.